Dasabuvir Sodium Hydrate

达塞布韦钠

Report date: 2026/05/13 20:02:10
NME

Base Information

Drug NameDasabuvir Sodium Hydrate
Drug Alias NameDasabuvir达塞布韦达萨布韦DasabuvirumExviera +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors
TargetsHepatitis C virus NS5B RNA-dependent RNA polymerase
Therapy Area/IndicationsDecompensated Liver CirrhosisFibrosisHypersensitivity +[8] 
Global Approved IndicationsHepatitis C, Chronic
Approved Indications in ChinaHepatitis C, Chronic
Original Approved Country/TerritoryEU
Original Approved Date2015/01/14
Country/TerritoryBelgiumBulgariaCanada +[33] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie Ag
Inactive CompaniesAbbott LaboratoriesAbbvie LtdAbbott Japan Co Ltd +[4] 
Active IndicationsHepatitis C, Chronic
Inactive IndicationsDecompensated Liver CirrhosisFibrosisHypersensitivity +[7] 

Other Information

ATC CodeJ05AP09
Related LinksWikipediaDrugBankKEGG